Related Experiment Video
Updated: Jun 14, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter
Si-Yuan Chen1, Peng-Peng Xu1, Ru Feng2
1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Cancer Communications (London, England)
|May 9, 2025
Summary
Diffuse large B-cell lymphoma (DLBCL) with extranodal involvement (ENI) has a poor prognosis, especially with multiple sites. Genetic subtype-guided immunochemotherapy shows promising efficacy in treating extranodal DLBCL.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma.
- Extranodal involvement (ENI) in DLBCL is associated with a poorer prognosis.
- Understanding the clinical and molecular features of ENI is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the clinical and molecular characteristics of extranodal involvement (ENI) in DLBCL.
- To assess the survival status of patients with extranodal DLBCL.
- To evaluate the efficacy of genetic subtype-guided immunochemotherapy for extranodal DLBCL.
Main Methods:
- A population-based cohort study of 5,023 newly diagnosed DLBCL patients.
- Analysis of clinical features, eligibility criteria, and sociodemographic details.
- Gene panel sequencing in 1,050 patients to identify molecular patterns associated with ENI.
Main Results:
- The 5-year overall survival rate for DLBCL was 67.9%.
- Specific sites like bone, bone marrow, and CNS were independent adverse prognostic factors.
- Multiple ENIs were linked to MYD88/CD79B mutations and poor prognosis, while genetic subtype-guided therapy improved survival rates.
Conclusions:
- DLBCL with multiple ENIs indicates a poor prognosis in the rituximab era.
- Genetic subtype-guided immunochemotherapy demonstrates efficacy in treating extranodal DLBCL.
- This study highlights the importance of molecular profiling for personalized treatment strategies.
